CPTx develops in vivo CAR-T and other genetic medicines using an immune-silent single-stranded DNA (ssDNA) platform. This technology leverages precision-engineered ssDNA and non-viral lipid nanoparticle delivery for durable expression and repeat dosing without viral vectors or mRNA. The company aims to make transformative cell therapies more accessible, affordable, and scalable for patients with cancer.
Funding
$29M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SDFounders
Product
Problem
Many infectious diseases require drugs that can target multiple binding sites to be effective, but traditional monovalent drug approaches are limited in their ability to address this complexity. Rapidly adapting to new viral strains and ensuring compatibility with different routes of administration also pose significant challenges in antiviral drug development.
Solution
CPTx develops programmable, single-stranded DNA therapeutics designed as rapid antiviral countermeasures. Their platform enables the precise design of multivalent drugs capable of targeting complex infectious diseases effectively. These therapeutics are engineered to reduce viral load and enhance the patient's immune response. The platform's flexibility supports the polyvalent presentation of drug molecules, crucial for addressing diseases with multiple binding sites.
Target Audience
The primary target audience includes patients suffering from complex infectious diseases, as well as medical professionals seeking advanced antiviral treatment options.
Features
- Programmable therapeutics platform for rapid development of antiviral countermeasures
- Single-stranded DNA products designed to reduce viral load and enhance immune response
- Multivalent drug design for targeting complex infectious diseases with multiple binding sites
- Biologically inert and compatible with different routes of administration